

# ceftAROLine

|  |   |
|--|---|
| BRAND NAME                             | ZINFORO   |
| DRUG CLASS                             | Cephalosporin antibiotic  |
| AVAILABILITY                           | Vial contains 600 mg of ceftaroline fosamil. Also contains L-arginine. <sup>1</sup>   |
| WARNINGS                               | Contraindicated in patients with severe immediate (IgE mediated) or severe delayed (T-cell mediated) hypersensitivity to penicillins. Seek specialist advice for patients with non-severe immediate hypersensitivity to penicillins.  |
| pH                                     | 5–7 when diluted <sup>1</sup>   |
| PREPARATION                            | Reconstitute the vial with 20 mL of water for injections to make an approximate concentration of 30 mg/mL. Shake well. The solution is pale yellow. <sup>1</sup><br>Further dilute the reconstituted solution immediately. <sup>1</sup><br>If a part-dose is required, reconstitute the vial with 19.3 mL of water for injections to make a concentration of 30 mg/mL. <sup>2</sup> Powder volume – 0.7 mL <sup>2</sup>   |
| STABILITY                              | Vial: store below 25 °C. Protect from light. <sup>1</sup><br>Reconstituted solution: dilute immediately. <sup>1</sup><br>Infusion solution: stable for 6 hours at room temperature or 24 hours at 2 to 8 °C. <sup>1</sup><br>For CoPAT use: solutions of 6 mg/mL in sodium chloride 0.9% are stable for 24 hours at 25 °C or 12 hours at 30 °C or 35 °C. Stability in glucose is reduced at higher temperatures. Solutions prepared in a sterile production unit are stable for 6 days at 4 °C. <sup>3</sup>  |
| ADMINISTRATION                         |   |
| <b>IM injection</b>                    | Not recommended   |
| <b>SUBCUT injection</b>                | Not recommended   |
| <b>IV injection</b>                    | Not recommended   |
| <b>IV infusion</b>                     | Dilute the dose in 50–250 mL of compatible fluid. The maximum concentration is 12 mg/mL. Infuse over 5 to 60 minutes. <sup>1</sup><br>High doses may be given as an extended infusion in critically-ill patients. <sup>1</sup> Check your local guidelines.   |
| <b>IV use for infants and children</b> | Dilute the dose to 12 mg/mL or less and infuse over 5 to 60 minutes. For children less than 2 months old, infuse over 30 to 60 minutes. <sup>1,4</sup>  |
| COMPATIBILITY                          |   |
| <b>Fluids</b>                          | Glucose 5% <sup>1</sup> , glucose 2.5% and sodium chloride 0.45% <sup>1</sup> , Hartmann's <sup>1</sup> , sodium chloride 0.9% <sup>1</sup>   |
| <b>Y-site</b>                          | Aciclovir <sup>5</sup> , aminophylline <sup>5</sup> , amiodarone <sup>5</sup> , azithromycin <sup>5</sup> , calcium chloride <sup>5</sup> , calcium gluconate <sup>5</sup> , ciclosporin <sup>5</sup> , ciprofloxacin <sup>5</sup> , cisatracurium <sup>5</sup> , clindamycin <sup>5</sup> , dexamethasone <sup>5</sup> , digoxin <sup>5</sup> , esomeprazole <sup>5</sup> , fentanyl <sup>5</sup> , fluconazole <sup>5</sup> , furosemide <sup>5</sup> , granisetron <sup>5</sup> , heparin sodium <sup>5</sup> , hydrocortisone sodium succinate <sup>5</sup> , hydromorphone <sup>5</sup> , insulin (Actrapid) <sup>5</sup> , lidocaine <sup>5</sup> , mannitol <sup>5</sup> , methylprednisolone sodium succinate <sup>5</sup> , metoclopramide <sup>5</sup> , metoprolol <sup>5</sup> , metronidazole <sup>5</sup> , midazolam <sup>5</sup> , milrinone <sup>5</sup> , morphine sulfate <sup>5</sup> , moxifloxacin <sup>5</sup> , noradrenaline (norepinephrine) <sup>5</sup> , pethidine <sup>5</sup> , potassium chloride <sup>5</sup> , promethazine <sup>5</sup> , ranitidine <sup>5</sup> , remifentanyl <sup>5</sup> , sodium bicarbonate <sup>5</sup> , trimethoprim-sulfamethoxazole <sup>5</sup> , voriconazole <sup>5</sup> |
| INCOMPATIBILITY                        |   |
| <b>Fluids</b>                          | No information  |
| <b>Drugs</b>                           | Aminoglycosides: amikacin, gentamicin, tobramycin <sup>1</sup> , caspofungin <sup>6</sup> , filgrastim <sup>6</sup> , fosfomycin <sup>6</sup> , isavuconazole <sup>6</sup> , labetalol <sup>6</sup> , potassium phosphates <sup>6</sup> , sodium phosphates <sup>6</sup>  |
| SPECIAL NOTES                          | Monitor the infusion site closely as infusion-site reactions are common and include erythema, phlebitis and pain. <sup>1</sup>  |

## REFERENCES

1. Product information. Available from [www.tga.gov.au](http://www.tga.gov.au). Accessed 28/04/2021.
2. Pfizer medical information. Pfizer enquiry INT-102254 [email]. Sydney: Pfizer; 03/03/2021.
3. Al Madfai F, Zaidi STR, Ming LC, Wanady T, Patel RP. Physical and chemical stability of ceftaroline in an elastomeric infusion device. *Eur J Hosp Pharm Sci Pract*. 2018; 25e: 115-9.
4. Taketomo C, Hodding J, Kraus D. Pediatric and neonatal dosage handbook. 27th ed. Hudson, Ohio: American Pharmacists Association. Lexicomp; 2020-2021.
5. McEvoy GK editor. Handbook on injectable drugs. 20th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2018.
6. Ceftaroline fosamil. In: IV index [internet]. Trissel's 2 clinical pharmaceuticals database (parenteral compatibility). Greenwood Village, CO: Truven Health Analytics. Accessed 28/04/2021.